TECOS is a phase III multinational trial, conducted in 38 countries across Australasia, Asia, Europe, North America, South America, India and South Africa.
TECOS Primary Results Presented At ADA
- 16 June 2015
Professor Rury Holman and Associate Professor Angelyn Bethel attended the annual American Diabetes Association conference in Boston to present the primary results of TECOS.
The Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) investigates whether giving people with type 2 diabetes a drug called sitagliptin alongside their usual diabetes care regime can reduce their risk of heart attacks and strokes. Co-ordinated by DTU and Duke Clinical Research Institute (DCRI), and sponsored by Merck & Co. Inc, the trial began in 2008 . The trial involves over 14,700 people with type 2 diabetes aged 50 years or older, who have heart and circulatory disease and whose blood glucose is not being controlled well. Each participant received either sitagliptin or a placebo (dummy drug) and are followed for three to five years. More information on the trial can be found on the DTU website